Thermo_Apr2021_The_mRNA_TherapeuticsBoom - 5

The POROS Oligo (dT)25 affinity resin demonstrates:
 Efficient elution at different load concentrations
The mRNA Theraptutics Boom	
 Excellent recovery with high purity independent of sample type used
Impurity analysis by HPLC
Absorbance, 260nm (mAU)

600
400

Improved impurity
clearance

Unpurified IVT mixture

Fig.3: Efficient removal

mRNA

Fig. 6 Efficient removal
of impurities compared
of impurities compared
to the spin column
to the spin column
method. HPLC analysis of
method. HPLC analysis of
unpurified IVT mixture,
unpurified IVT mixture,
spin column
purified purified
spin
column
mRNA
and
mRNA
mRNA and mRNA purified
purified
with POROS
with
POROS
Oligo (dT)25
Oligo
(dT)25
resin.
resin.

15.7%

200
0
150
100

Current spin column purification method

13.4%

50
0
300
200
100
0
0.0

Purified with POROS Oligo (dT)25 resin

6.2%
7.0

2.0

4.0

6.0

8.0

8.0

9.0

10.0

Time (min)

 Purification with POROS Oligo (dT)25 resin leads to significant
reductionasof
" In reverse-phase,
theimpurities
column is reused, the impuIndurthi. " It works really well for our applications and
rities start to follow the column, and that can change
will be added to our repertoire for mRNA production. "
the column's effectiveness, " says Flook. With POROS
CONCLUSIONS
Oligo (dT)25 resin, the impurities are removed without
Looking to the Future
first
binding
them to
the column,
rendering
The
POROS
Oligo
(dT)25
resin the
addresses the current challenges involved
COVID mRNA vaccines are expanding the already
number
of impurities
irrelevant.
resin is reusableused The
with large
scale
mRNAThe
purification
in potential mRNA-based therapies.
significant
interest in the RNA space and taken mRNA
and base stable for in-place sanitization.
manufacturing to a new level. Going forward, the
" Each
is designed
a specific application; the
UsemRNA
of this
resin for
will:
biggest bottlenecks will be the DNA templates and
Cadillac version of purification is not always required.
the enzymes needed for synthesis. Luckily, the boom
have
Simplify
mRNA
downstream
We
differentyour
purification
strategies
for different process
has also catapulted development activity in resins,
 Increase
applications,
" says purity
Indurthi. and
" As anyield
example, if mRNA is
nucleotides, and enzymes.
 Allow
scalable
mRNA
purification
process without the use of toxic
being
used forfor
a vaccine,
you do
not need
to get rid
Hurdles still remain for mRNA therapeutics for different
of certain
impurities, but if you are making RNA for
chemicals
indications. One of the challenges is how to get the
therapeutic use, you do because they will trigger an
mRNA to
theallow
right cells,
targeting
Customer
testimonial
will
us toespecially
meet thewhen
increasing
unwanted
immune
response. " - " This promising technology
specific
cancers.
" We
are
going
to
see
a
lot
demands of mRNAs from our customers " - Peter Scheinert, CEO AmpTec of developIn general, oligo dT purification can be used as a
ment around delivery systems, " says Flook.
Samples used were kindly provided by AmpTec
stand-alone purification. " We have seen pure RNA
However, these challenges will not change the moleusing this approach; it is a better way. The purer the
cule's current trajectory. mRNA therapeutics are poised
TRADEMARKS/LICENSING
end
product, the less you need to get a response, " says
become
important
element
in otherwise
the healthcare
© 2020 Thermo
Fisher Scientific
Inc. All rightssize,
reserved.
trademarks
are the property to
of Thermo
Fisheran
Scientific
and its subsidiaries
unless
specified.
Indurthi.
" Secondary
structure,
andAll other
factors
This information is not intended to encourage use of these products in any manner that might infringe the intellectual property rights of others.
n
landscape
in
the
coming
years.
affect the recovery, not the resin itself. "
Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only.

" With all of the oligo dT resins we have tested, we
observed that POROS Oligo (dT)25 has a very high
binding capacity and provides the ability to purify
larger mRNAs as compared to other products, " adds
5 | GENengnews.com

References:
Wolff J.A. et al. Science 247, 1465-1468 (1990)
Martinon F.et al. Eur J Immunol 23, 1719-1722 (1993)
Pharmaceutical Grade Reagent. For Manufacturing and Laboratory Use Only.



https://www.thermofisher.com/us/en/home.html https://www.genengnews.com

Thermo_Apr2021_The_mRNA_TherapeuticsBoom

Table of Contents for the Digital Edition of Thermo_Apr2021_The_mRNA_TherapeuticsBoom

Thermo_Apr2021_The_mRNA_TherapeuticsBoom - 1
Thermo_Apr2021_The_mRNA_TherapeuticsBoom - 2
Thermo_Apr2021_The_mRNA_TherapeuticsBoom - 3
Thermo_Apr2021_The_mRNA_TherapeuticsBoom - 4
Thermo_Apr2021_The_mRNA_TherapeuticsBoom - 5
https://www.nxtbookmedia.com